Godsey & Gibb Inc. Sells 92 Shares of Eli Lilly and Company (NYSE:LLY)

Godsey & Gibb Inc. lowered its position in Eli Lilly and Company (NYSE:LLY) by 7.7% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,100 shares of the company’s stock after selling 92 shares during the period. Godsey & Gibb Inc.’s holdings in Eli Lilly and Company were worth $849,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in LLY. Beck Bode LLC bought a new stake in shares of Eli Lilly and Company during the second quarter worth $15,036,000. Seven Eight Capital LP increased its holdings in Eli Lilly and Company by 146.3% during the 2nd quarter. Seven Eight Capital LP now owns 2,118 shares of the company’s stock worth $1,918,000 after purchasing an additional 1,258 shares in the last quarter. Carolinas Wealth Consulting LLC raised its stake in shares of Eli Lilly and Company by 14.3% in the 2nd quarter. Carolinas Wealth Consulting LLC now owns 320 shares of the company’s stock valued at $289,000 after purchasing an additional 40 shares during the period. Sienna Gestion lifted its holdings in shares of Eli Lilly and Company by 15.7% in the second quarter. Sienna Gestion now owns 14,383 shares of the company’s stock valued at $13,016,000 after purchasing an additional 1,949 shares in the last quarter. Finally, Altrius Capital Management Inc boosted its position in shares of Eli Lilly and Company by 7.2% during the second quarter. Altrius Capital Management Inc now owns 1,272 shares of the company’s stock worth $1,152,000 after buying an additional 85 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling

In other news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $758.70 on Friday. The company has a market cap of $720.25 billion, a P/E ratio of 82.02, a P/E/G ratio of 1.66 and a beta of 0.41. The firm’s fifty day moving average price is $784.03 and its two-hundred day moving average price is $856.70. Eli Lilly and Company has a one year low of $612.70 and a one year high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). The company had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business’s quarterly revenue was up 20.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.10 EPS. Equities analysts expect that Eli Lilly and Company will post 13.14 earnings per share for the current year.

Eli Lilly and Company declared that its board has approved a share repurchase program on Monday, December 9th that allows the company to buyback $15.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 2% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.79%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio (DPR) is 56.22%.

Wall Street Analyst Weigh In

LLY has been the topic of several research reports. Bank of America restated a “buy” rating and issued a $997.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Citigroup increased their target price on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a report on Friday, October 25th. Barclays lowered their price target on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Truist Financial increased their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Finally, Sanford C. Bernstein began coverage on Eli Lilly and Company in a research report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,002.22.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.